title: Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.
abstract: Thrombocytopenia-associated multiple organ failure (TAMOF) is a clinical phenotype that encompasses a spectrum of syndromes associated with disseminated microvascular thromboses, such as the thrombotic microangiopathies thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) and disseminated intravascular coagulation (DIC). Autopsies findings in TTP, HUS, or DIC reveal specific findings that can differentiate these 3 entities. Von Willebrand factor and ADAMTS-13 play a central role in TTP. Shiga toxins and the complement pathway are vital in the development of HUS. Tissue factor is the major protease that drives the pathology of DIC. Acute kidney injury (AKI) is a common feature in patients with TAMOF.
authors.affiliation: Section of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Center for Translational Research on Inflammatory Diseases (CTRID), Michael DeBakey VA Medical Center, Houston, TX 77030, USA. Electronic address: tcnguyen@texaschildrenshospital.org.
authors.forename: Trung C
authors.initials: TC
authors.lastname: Nguyen
authors.affiliation: Department of Medicine, Baylor College of Medicine, Center for Translational Research on Inflammatory Diseases (CTRID), Michael DeBakey VA Medical Center, Houston, TX 77030, USA.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Cruz
authors.affiliation: Department of Critical Care Medicine and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Carcillo
mesh_terms: D051722:ADAM Proteins / Q000097:blood / Q000235:genetics; D000071120:ADAMTS13 Protein; D058186:Acute Kidney Injury / Q000209:etiology* / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D003165:Complement System Proteins / Q000378:metabolism; D004211:Disseminated Intravascular Coagulation / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D006463:Hemolytic-Uremic Syndrome / Q000150:complications* / Q000235:genetics / Q000382:microbiology / Q000628:therapy; D006801:Humans; D009102:Multiple Organ Failure / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000150:complications* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D022603:Shiga Toxins / Q000378:metabolism; D013925:Thromboplastin / Q000378:metabolism; D014841:von Willebrand Factor / Q000235:genetics / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D051056:Complement Inactivating Agents; D022603:Shiga Toxins; D014841:von Willebrand Factor; D003165:Complement System Proteins; D013925:Thromboplastin; C481642:eculizumab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human
keywords: ADAMTS-13; AKI; DIC; HUS; Platelet; TAMOF; TTP; VWF